Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, mol...
Saved in:
| Main Authors: | Samuel Theodorus Sutanto, Robert Sinto, Adeline Pasaribu, Sharifah Shakinah |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2023-01-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01) -
Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
by: Rani Sawtell, et al.
Published: (2025-12-01) -
Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01) -
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
by: Yuchen Wei, et al.
Published: (2025-12-01) -
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)